Michael Lee Brooks - Mar 2, 2022 Form 4 Insider Report for Syneos Health, Inc. (SYNH)

Role
Chief Development Officer & Global Head Clinical Development Solutions
Signature
/s/ Sara Epstein, Attorney-in-Fact
Stock symbol
SYNH
Transactions as of
Mar 2, 2022
Transactions value $
$0
Form type
4
Date filed
3/4/2022, 04:03 PM
Previous filing
Feb 18, 2022
Next filing
May 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYNH Class A Common Stock Award $0 +1.32K +3.73% $0.00 36.8K Mar 2, 2022 Direct F1
holding SYNH Class A Common Stock 10.8K Mar 2, 2022 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents performance restricted stock units that were earned based upon performance criteria for the year ended December 31, 2021 and will vest in full once the Compensation and Management Development Committee of the Board of Directors of Syneos Health, Inc. determines the attainment level of the performance goals for the year ended December 31, 2023, subject to continued employment.

Remarks:

Chief Development Officer & Global Head Clinical Development Solutions